Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atriva Therapeutics GmbH

http://atriva-therapeutics.com/

Latest From Atriva Therapeutics GmbH

Atriva: Targeting Patients, Not Virus, Is The Way Forward In Flu

Emerging Company Profile: Four-year-old Atriva Therapeutics GmbH is developing a drug to prevent the proliferation of flu virus by transiently inhibiting one of the patient’s own cellular processes, a host-mediated novel mechanism of action that could be effective against a range of respiratory virus infections.

StartUps and SMEs Infectious Diseases

Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed

A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.

StartUps and SMEs Financing

Venture Funding Deals

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.

Commercial StartUps and SMEs

Tech Transfer Deals, July 2016: Kite Moves Toward Off-The-Shelf T-Cell Therapy

Kite licenses allogeneic cell technology from UCLA that may enable it to create off-the-shelf T-cell therapeutics, augmenting its ongoing development of autologous cancer therapies. See Scrip's monthly update on licensing agreements between companies and universities or other research institutions.

Deals Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Atriva Therapeutics GmbH
  • Senior Management
  • Rainer Lichtenberger, CEO
    Sebastian Canisius, MD, PhD, CMO
    Oliver Planz, PhD, CSO
    Henrik Luessen, PhD, CBO
  • Contact Info
  • Atriva Therapeutics GmbH
    Phone: 7071 8597673
    Tübingen,
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register